Speakers / Chairs icon
Speakers / Chairs
Exhibition icon
Exhibition
Abstracts icon
Abstracts
Information icon
Information
Live icon
Live
Awards icon
Awards
Information icon
Information
Information icon
Information
Information icon
Information
Archive icon
Archive
Saturday 12.10.2013
Scientific Session
Satellite Symposium
Main Program
Hematology Educational
Workshop
calendar export icon
Export calendar
Chronic Lymphocytic Leukemia (CLL)
Mantle Cell Lymphoma (MCL)
Aggressive Non-Hodgkin-Lymphoma (NHL)
Chronic Myeloid Leukemia (CML)
The immunomodulatory and angiogenic protein Galectin 1 is a circulating biomarker in Hodgkin Lymphoma
Plasma TARC as a treatment response marker and prognostic tissue biomarkers in classical Hodgkin Lymphoma
Prognostic biomarkers from gene expression pro ling in formalin- xed para n-embedded biopsies
Flow cytometry studies of lymphocyte predominant cells from nodular Lymphocyte Predominant Hodgkin Lymphoma
Identication of CD8 ‘follicularcytotoxic’ cells in tumor infiltrating T cells from classical Hodgkin Lymphoma
Overview of international harmonization of staging and response criteria in pediatric Hodgkin Lymphoma – summary of results thus far
Highlights and controversies found between existing major pediatric groups
New concepts of eld and dose: Implications for disease control and long-term outcome
The role of radiotherapy in early stage and the relevance of PET response
Is radiotherapy still relevant for patients with advanced stage disease and in salvage of chemotherapy failures?
Progress on new drug development in Hodgkin Lymphoma
Clinical trials design, response assessment, and trial end points
Challenges of translation of abundant new data into clinical trials in rare diseases
Challenges of preclinical models
Optimizing and using imaging for RT planning
Advanced conformal RT for reduction of normal organ exposure
Techniques for reduction of breast exposure
Proton therapy for Hodgkin Lymphoma
Early detection of breast cancer
The new NCCN guidelines and the role of PET / CT
Imaging and PET / CT recommendations for the revised staging and response criteria
Metabolic tumor volume and other new concepts
qPET – a quantitative approach to assess response in interim FDG-PET scans in lymphoma
Novel and recurrent coding sequence mutations in microdissected Hodgkin-/ Reed- Sternberg cells
No chance for a comeback? The multiple ways to block the B-cell phenotype in Hodgkin Lymphoma
New insights into the transcription factor network of Hodgkin-/ Reed-Sternberg cells
Transcriptome analysis of Hodgkin and Reed-Sternberg cells enriched from Hodgkin Lymphoma biopsies: an approach to virus discovery
Downregulation of FOXO1 prevents induction of the tumor suppressor PRDM1 in cHL
RAPID trial: Update and lessons in standardized interpretation of PET
BCCA experience: Population-based PET guided treatment
Challenges applying PET for early stage disease
What did EORTC H10 teach us?
Formulation of conclusions and identi cation of important outstanding questions
Some “philosophical” introductoryremarkson the need and pitfalls of long-term follow-up
The ASCO and the Dutch guidelines
Minimizing treatment and its consequences for long term toxicity and follow-up
Reducing RT to involved node principle and its consequences for long-term toxicity and follow-up
General discussion
Familial risks and germline genetics of Hodgkin Lymphoma
HLA locus and risk of Hodgkin Lymphoma
Multiple neoplasias a er Hodgkin Lymphoma; incidence and risk factors
Genetic defects of T-cell function predisposing for EBV-associated lymphoproliferation and Hodgkin Lymphoma
General discussion
New approaches in the treatment of mantle cell and other Non Hodgkin Lymphoma
New horizons in the treatment o CLL
Sunday 13.10.2013
Scientific Session
Satellite Symposium
Main Program
Hematology Educational
Workshop
calendar export icon
Export calendar
Session details
07:30–08:30
Satellite Symposium
Novel Methodology to aid in the Diagnosis of Difficult Hodgkin Lymphoma Cases
Room: Großer Saal
Introduction and Perspective
Novel methodology to aid in the diagnosis of di cult lymphoma cases
Case Series Presentation using MultiOmyx Methodology
Questions & Answers
Non-coding RNA and tumor cell survival
Integrated genomic analysis of ow sorted Hodgkin and Reed-Sternberg cell in primary classical Hodgkin Lymphoma
TCF3 / E2A (19p13.3) is a novel Hodgkin Lymphoma susceptibility locus; a meta-GWAS study from the InterLymph Hodgkin Lymphoma consortium
Hodgkin-Reed-Sternberg cells in classical Hodgkin Lymphoma show alterations of genes encoding the NADPH oxidase complex and impaired reactive oxygen species synthesis capacity
Rationale and Clinical Experience with Lenalidomide in Hodgkin Lymphoma
Progress in the treatment of Aggressive B-Cell Lymphomas
Emerging treatment options for mantle cell lymphoma
Session details
14:00–15:15
Satellite Symposium
New Insights in the Treatment and Management of Lymphoid Malignancies
Room: Großer Saal
New Aspects on Dose Density in Malignant Lymphoma
The impact of hematological toxicity in Hodgkin Lymphoma
Bispeci c CD19 antibodies – a new treatment principle for management of relapsed / refractory ALL and NHL
Session details
16:00–17:30
Satellite Symposium
Relapsed/Refractory Hodgkin Lymphoma: Exploring Targeted Therapeutic Options
Room: Großer Saal
The challenge of relapsed Hodgkin Lymphoma in the era of contemporary therapy
Q&A
Defining the ideal target in Hodgkin Lymphoma
Q&A
Targeting CD30 with monoclonal antibody- based constructs
Q&A
Current success and future opportunities with targeted therapy in Hodgkin Lymphoma
Q&A
Bonadonna Lecture: The Hodgkin puzzle: Are we getting close?
Awards Ceremony
Monday 14.10.2013
Scientific Session
Satellite Symposium
Main Program
Hematology Educational
Workshop
calendar export icon
Export calendar
Do we have a new backbone in CLL?
Can we make MabThera better?
Microenvironment in Hodgkin Lymphoma
Molecular pathogenesis of Hodgkin Lymphoma
Deregulation of di erentiation in pathogenesis of cHL
Plasma microRNA are disease response biomarkers in classical Hodgkin Lymphoma
CD57+ T cells in nodular lymphocyte predominant Hodgkin Lymphoma are
T-follicular helper cells
Analysis of myeloid suppressor marker Arginase identi es CD68+ / Arginase+ myeloid / monocytic subsets and exerts stronger prognostic in uence than macrophage quanti cation in Classical Hodgkin Lymphoma
Update on the NCRI RAPID trial
An update on the EORTC / LYSA / FIL H10 trial
WS report and further optimization in early stage Hodgkin Lymphoma
Impact of bleomycin and dacarbazine within the ABVD regimen in the treatment of early-stage favorable Hodgkin Lymphoma: Final results of the GHSG HD13 trial
De nition of bulky disease in early stage Hodgkin Lymphoma in computed tomography era: Prognostic signi cance of measurements in the coronal and transverse planes
Brentuximab vedotin plus AVD as initial therapy of non-bulky limited stage classical Hodgkin Lymphoma: Interim analysis of an ongoing phase II trial
Introduction “Let’s get interactive”
Do we need G-CSF in Lymphoma Therapy?
How much G-CSF is necessary in Lymphoma Therapy?
Current clinical Lymphoma trials based on G-CSF
Innovation and Best Practice – how to bene t
Relapsed / refractory Hodgkin Lymphoma in older patients
GHSH phase I / II trial of AVD-Rev (adriamycin, vinblastin, dacarbacine and lenalidomide) for older Hodgkin Lymphoma patients
Sequential brentuximab vedotin (BV) and adriamycin, vinblastine, and dacarbazine (AVD) for older patients with untreated Hodgkin Lymphoma (HL): Preliminary toxicity ndings from a phase II window study
Treatment outcome in 111 elderly patients with Hodgkin Lymphoma: a retrospective analysis
PET for early response prediction
PET review in GHSG trials
PETinrelapsedorrefractoryHodgkinLymphoma
Response-adapted therapy of stage III-IV Hodgkin lymphoma based on interim FDG-PET imaging: early results of US intergroup S0816
Very early response as measured by (18F)- uorodeoxyglucose-positron emission tomography (FDG-PET) a er one cycle of chemotherapy in newly diagnosed pediatric / adolescent low risk Hodgkin Lymphoma (HL)
Tailored therapy in Hodgkin Lymphoma, based on prede ned risk factors and early interim PET / CT, Israeli H2 protocol: Preliminary report on 317 patients
Tuesday 15.10.2013
Scientific Session
Satellite Symposium
Main Program
Hematology Educational
Workshop
calendar export icon
Export calendar
Session details
07:30–09:00
Workshop 13
Beyond the International Harmonization Criteria – New challenges in the application of imaging techniques for staging and response
Room: Großer Saal
Practical experience in the application of the International Harmonization Criteria – as viewed by a medical oncologist
Anatomic imaging challenges of the International Harmonization Criteria
Nuclear medicine aspects of the International Harmonization Criteria, as they apply to pediatrics
Overview of the challenges encountered by the Pediatric International Harmonization Criteria Workshop
Breast Cancer and other Neoplasms
Changes in breast cancer risk as long-term Hodgkin Lymphoma survivors reach menopausal age
Second cancer risk forty years a er cure for Hodgkin Lymphoma
A Dutch nationwide survivorship care programme for Hodgkin Lymphoma survivors
Risk-adapted therapy in advanced stage Hodgkin Lymphoma: An Update
Impact of dose reductions of bleomycin and vincristine in patients with advanced Hodgkin Lymphoma treated with BEACOPP polychemotherapy:
A comprehensive analysis of the German Hodgkin Study Group (GHSG) HD12 and HD15 trials
Standard ABVD vs. escalated BEACOPP in stage III – IV low risk Hodgkin Lymphoma (IPS 0-2): the Lymphoma Study Association (LYSA) H34 trial
Response rates and toxicity of response-adapted therapy in advanced Hodgkin Lymphoma: initial results from the international RATHL study
Introduction
Clinical infectious challenges in patients with Hodgkin Lymphoma
Present and upcoming vaccines for the immunocomprised host
Focussing on unmet medical needs in abdominal infections
What’s new in relapsed Hodgkin Lymphoma?
Debate: Is there still a role for allogeneic
TX in Hodgkin Lymphoma?
Phase 2 study everolimus for relapsed / refractory classical Hodgkin Lymphoma (cHL)
Outcome of patients treated with autologous stem-cell transplantation for rst relapsed or refractory Hodgkin Lymphoma: A long-term analysis of the prospective LYSA / SFGM-TC H96 trial
PET adapted sequential salvage therapy with brentuximab vedotin and augmented ICE for transplant eligible patients with relapsed and refractory Hodgkin Lymphoma
Prognostic indices and PET
Speaker details
Jeremy S.
Abramson
Speaker details
Berthe
Aleman
Speaker details
Marc
André
Speaker details
Stephen
Ansell
Speaker details
James
Armitage
Speaker details
Karolin
Behringer
Speaker details
Kirsten
Bienemann
Speaker details
Magnus
Björkholm
Speaker details
Boris
Böll
Speaker details
Peter
Borchmann
peter.borchmann@uk-koeln.de
12.10.,
12:00–13:30,
Challenges in the development of new drugs in HL
(Chair, Speaker)
12.10.,
18:00–19:00,
Targeted Therapy: The Future in the Treatment of Malignant Lymphoma
(Chair)
13.10.,
08:30–10:00,
Interactive Case Discussions
(Chair)
13.10.,
14:00–15:15,
New Insights in the Treatment and Management of Lymphoid Malignancies
(Speaker)
15.10.,
11:00–12:30,
Advanced Stages
(Speaker)
Speaker details
Sven
Borchmann
Speaker details
Patrice
Carde
Speaker details
Franco
Cavalli
Speaker details
Bruce
Cheson
Speaker details
Bertrand
Coiffier
Speaker details
Oliver A.
Cornely
Speaker details
Bouthaina
Dabaja
Speaker details
Eldad J.
Dann
Speaker details
Andrew
Davis
Speaker details
Nicky
Dekker
Speaker details
Volker
Diehl
Speaker details
Arjan
Diepstra
Speaker details
Markus
Dietlein
Speaker details
Meletios-Athanassios
Dimopoulos
Speaker details
Martin
Dreyling
Speaker details
Andreas
Engert
a.engert@uni-koeln.de
12.10.,
12:00–13:30,
GHSG Workshop
(Chair)
12.10.,
16:00–17:30,
Integrating PET into the management of early stage HL
(Chair, Speaker)
13.10.,
12:15–13:45,
Lenalidomide in Lymphoma – Latest Update on Clinical Data
(Chair)
13.10.,
16:00–17:30,
Relapsed/Refractory Hodgkin Lymphoma: Exploring Targeted Therapeutic Options
(Chair, Speaker)
14.10.,
07:30–08:30,
Beyond the revolution of MabThera
(Chair)
15.10.,
07:30–09:00,
Beyond the International Harmonization Criteria – New challenges in the application of imaging techniques for staging and response
(Chair)
15.10.,
20:00,
Closing Remakrs
(Chair)
14.10.,
10:30–12:00,
Early Stages
(Speaker)
Speaker details
Andrew
Evens
Speaker details
Massimo
Federico
Speaker details
Richard
Fisher
Speaker details
Alexander
Fosså
Speaker details
Jonathan
Friedberg
Speaker details
Jonathan
Fromm
Speaker details
Michael
Fuchs
Speaker details
Andrea
Gallamini
Speaker details
Randy
Gascoyne
Speaker details
Maciej
Giefing
Speaker details
Christian
Gisselbrecht
Speaker details
Nicola
Gökbuget
Speaker details
Anton
Hagenbeek
Speaker details
Michael
Hallek
Speaker details
Dirk
Hasenclever
Speaker details
Jens
Hasskarl
Speaker details
Kari
Hemminki
Speaker details
David
Hodgson
Speaker details
Richard
Hoppe
Speaker details
Michael
Hummel
Speaker details
Martin
Hutchings
Speaker details
Tim
Illidge
Speaker details
Martin
Janz
Speaker details
Ruth
Jarrett
Speaker details
Peter
Johnson
Speaker details
Patrick
Johnston
Speaker details
Kimberley
Jones
Speaker details
Frank G.
Keller
Speaker details
Kara
Kelly
Speaker details
Eva
Kimby
Speaker details
Wolfram
Klapper
Speaker details
Richard
Klasa
Speaker details
Regine
Kluge
Speaker details
Wolfgang
Knauf
Speaker details
Dieter
Körholz
Speaker details
Anita
Kumar
Speaker details
Paul
La Rosee
Speaker details
Judith
Landman-Parker
Speaker details
Hartmut
Link
Speaker details
Andrew
Lister
Speaker details
Per
Ljungman
Speaker details
Stephan
Mathas
Speaker details
Peter
Meidahl Petersen
Speaker details
Monika
Metzger
Speaker details
George
Mikhaeel
Speaker details
Franck
Morschhauser
Speaker details
Alison
Moskowitz
Speaker details
Craig H.
Moskowitz
Speaker details
Nicolas
Mounier
Speaker details
Andrea
Ng
Speaker details
Grzegorz S.
Nowakowski
Speaker details
Helmut
Ostermann
Speaker details
Livio
Pagano
Speaker details
Karl
Peggs
Speaker details
Ruth
Pettengell
Speaker details
Michael
Pfreundschuh
Speaker details
Stefano
Pileri
Speaker details
Aaron
Polliack
Speaker details
Oliver
Press
Speaker details
Stephen J.
Proctor
Speaker details
John
Radford
Speaker details
John
Raemaekers
Speaker details
Klaus
Rajewsky
Speaker details
Jonathan
Reichel
Speaker details
Umberto
Ricardi
Speaker details
Andreas
Rosenwald
Speaker details
Ahmad
Sattarzadeh
Speaker details
Michael
Schaapveld
Speaker details
Norbert
Schmitz
Speaker details
Lawrence H.
Schwartz
Speaker details
Margaret
Shipp
Speaker details
Lena
Specht
Speaker details
Aspasia
Stamatoullas
Speaker details
Christian
Steidl
Speaker details
Harald
Stein
Speaker details
Anna
Sureda
Speaker details
Hauke
Thomsen
Speaker details
Anke
van den Berg
Speaker details
Flora
van Leeuwen
Speaker details
Maria J.
Vehreschild
Speaker details
Martin
Vogelhuber
Speaker details
Bastian
von Tresckow
Speaker details
Julie
Vose
Speaker details
Lawrence
Weiss
Speaker details
Thomas
Wirth
Speaker details
Julia S.
Wong
Speaker details
Luc
Xerri
Speaker details
Joachim
Yahalom
Speaker details
Anas
Younes
younesa@mskcc.org
12.10.,
12:00–13:30,
Challenges in the development of new drugs in HL
(Chair, Speaker)
12.10.,
18:00–19:00,
Targeted Therapy: The Future in the Treatment of Malignant Lymphoma
(Speaker)
15.10.,
07:30–09:00,
Beyond the International Harmonization Criteria – New challenges in the application of imaging techniques for staging and response
(Speaker)
13.10.,
16:00–17:30,
Relapsed/Refractory Hodgkin Lymphoma: Exploring Targeted Therapeutic Options
(Speaker)
15.10.,
16:15–18:00,
Milestones in Hodgkin Lymphoma
(Speaker)
Speaker details
Pier Luigi
Zinzani
Basement
shift key
Hold SHIFT key while scrolling to zoom the map.
Hold ALT key while scrolling to rotate the map.
pinch-gesture
Use two fingers to zoom, move, or rotate the map.
Floor plan of Basement
Wardrobe
Go to Ground Floor
Go to Ground Floor
Weinkeller
Basement
First Floor
shift key
Hold SHIFT key while scrolling to zoom the map.
Hold ALT key while scrolling to rotate the map.
pinch-gesture
Use two fingers to zoom, move, or rotate the map.
Floor plan of First Floor
Go to Ground Floor
Go to Ground Floor
Großer Saal
First Floor
Dorint Hotel: Ground Level
shift key
Hold SHIFT key while scrolling to zoom the map.
Hold ALT key while scrolling to rotate the map.
pinch-gesture
Use two fingers to zoom, move, or rotate the map.
Floor plan of Dorint Hotel: Ground Level
Go to Ground Floor
Go to Ground Floor
Go to First Floor
Pipin II
Sandkaul
Pipin I
Dorint Hotel: Ground Level
Dorint Hotel: First Floor
shift key
Hold SHIFT key while scrolling to zoom the map.
Hold ALT key while scrolling to rotate the map.
pinch-gesture
Use two fingers to zoom, move, or rotate the map.
Floor plan of Dorint Hotel: First Floor
Go to Ground Level
Martin
&
Augustin
Severin
Dorint Hotel: First Floor
Exhibition
shift key
Hold SHIFT key while scrolling to zoom the map.
Hold ALT key while scrolling to rotate the map.
pinch-gesture
Use two fingers to zoom, move, or rotate the map.
Map of the exhibition.
Map of the First Floor showing the location of 0 exhibitors.
Stair to Ground Floor
Stair to Ground Floor
Großer Saal